SavedAdd your journal

Journals / Erciyes Tıp Dergisi / 2005 / Cilt: 27 - Sayı: 4

Immunohistochemical expression of c-erbB-2, PCNA, p53, bcl-2, FVIII in stage II-III invasive ductal carcinoma

Evre II-III invaziv duktal karsinom olgularında c-erbB-2, PCNA, p53, bcl-2, FVIII immunreaktivitesi

Serdar SOYUER
Metin ÖZKAN
Figen ÖZTÜRK
Işın SOYUER
Turhan ÖKTEN
Özlem CANÖZ
Pages
141–146
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No significant correlation was found between p53, PCNA, bcl-2, FVIIIRA and c-erbB-2 status with morphological type, tumor size, estrogen and progesterone hormone receptor status except that multivariate and chi-square tests showed C-erB-2 positive correlation with tumor histological grade (p= 0.024 p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The object of the present study is to detect the p53 tumor supressor gene and proliferating cell nuclear antigen (PCNA), c-erbB-2, bcl-2, FVIII related antigen (FVIIIRA) expression in breast carcinoma by immunohistochemistry, and the correlation with prognostic parameters.Material and Methods: A total of 55 cases with primary breast carcinoma were studied and classified histopathologically using modified Bloom and Richardson.
📊
Key Findings & Data:Paraffin sections were stained by using monoclonal antibody p53 protein, PCNA, c-erbB-2, bcl-2, FVIIIRA.Results: Of the 55 cases, 23 (41.81%) were p53 positive and 41 (74.54 %) were PCNA positive.
💡
Conclusion & Impact:No significant correlation was found between p53, PCNA, bcl-2, FVIIIRA and c-erbB-2 status with morphological type, tumor size, estrogen and progesterone hormone receptor status except that multivariate and chi-square tests showed C-erB-2 positive correlation with tumor histological grade (p= 0.024 p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: The object of the present study is to detect the p53 tumor supressor gene and proliferating cell nuclear antigen (PCNA), c-erbB-2, bcl-2, FVIII related antigen (FVIIIRA) expression in breast carcinoma by immunohistochemistry, and the correlation with prognostic parameters.Material and Methods: A total of 55 cases with primary breast carcinoma were studied and classified histopathologically using modified Bloom and Richardson. Paraffin sections were stained by using monoclonal antibody p53 protein, PCNA, c-erbB-2, bcl-2, FVIIIRA.Results: Of the 55 cases, 23 (41.81%) were p53 positive and 41 (74.54 %) were PCNA positive. The mean PCNA labelling index (PCNA LI +/- SD) was58.21+/-25.12. Maximum p53 and PCNA positivity was observed in grade III tumors (52.43% and 85.45%). The mean PCNA LI +/- SD was also highest in grade III carcinomas (62.67+/-12.85). No significant correlation was found between p53, PCNA, bcl-2, FVIIIRA and c-erbB-2 status with morphological type, tumor size, estrogen and progesterone hormone receptor status except that multivariate and chi-square tests showed C-erB-2 positive correlation with tumor histological grade (p= 0.024 p

Özet

Amaç:Bu çalışmanın amacı; invaziv meme karsinomlarında; p53 tümör baskılayıcı gen, proliferation cell nuclear antigen (PCNA), c-erbB-2, bcl-2, FVIII’in immunohistokimyasal (IHK) olarak belirlenmesi ve sonuçların diğer prognostik belirleyiciler ile karşılaştırılarak değerlendirilmesidir. Gereç ve Yöntem: Primer meme karsinomu olan 55 olgu çalışmaya alındı ve histopatolojik olarak modifiye Bloom ve Richardson kriterlerine göre sınıflandırıldı. Parafin kesitler monoklonal antikorlar, p53 protein, PCNA, c-erbB-2, bcl-2, FVIII ile İHK olarak boyandı.Bulgular:Olgularımızın 23’ü (%41,8) p53 pozitif ve 41’i (%74.54) PCNA pozitif boyandı. Ortalama PCNA boyanma indeksi (PCNA LI +/- SD) 58.21+/-25.12 olarak bulundu. IHK olarak p53 ve PCNA pozitifliği en yoğun, evre III tümörlerde (%52.43 ve %85.45) izlendi. Aynı zamanda ortalama PCNA LI evre III karsinomlarda en yüksek düzeyde saptandı (62.67+/-12.85). C-erbB-2 pozitifliği ile tümörün histolojik evresi (p= 0.024 p

🔖

Cite This Article

SOYUER, S., ÖZKAN, M., ÖZTÜRK, F., SOYUER, I., ÖKTEN, T., CANÖZ, Ö. (2022). Immunohistochemical expression of c-erbB-2, PCNA, p53, bcl-2, FVIII in stage II-III invasive ductal carcinoma. Erciyes Tıp Dergisi, Cilt: 27 - Sayı: 4, 141–146. https://ajindex.com/articles/502822

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Narita M, Nakao K, Ogino N, et al. Independent prognostic factors in breast cancer patients Am J Surg 1998; 175:73-75
  2. Jacquamier JD, Llorca FMP, Bertucci F, et al. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemoterapy. J Pathol 1998;184:130-135. 3-De Jong J, Van Diest PJ, Van Der Valk P, Baak JB. Expression of growth factors, growth-inhibiting factors, and their receptors in invazive breast cancer. II. Correlations with proliferation and angiogenesis. J Pathol 1998;184:53-57. 4-Prosser J, Thompson AM, Cranston G, Evans HJ. Evidence that p53 behaves as a tumor supressor gen in a sporadic breast tumours. Oncogene 1990;5:1573-1579. 5-Thompson AM, Steel CM, Chetty U, et al. P53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 1990;61:74-78. 6-Casey G, Lo Hosueh M, Lopez ME, Vogeistein B, Stanbridge EJ. Growth supression of human breast cancer cells by the introduction of a wild type p53 gene. Oncogene 1991;6:1791- 1797. 7-Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW. HER-2/neu oncogene expression and proliferation in breast cancer. Am J Pathol 1990;137:103-111. 8-Maguire HC, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol. 1989;16:148-155. 9-Van De Vijver MJ, Petere JL, Mool VJ et al. Neu-protein overexpression in breast cancer. N Engl J Med. 1988;319:1239- 1245. 10-Van Diest PJ, Baak JPA, Chin D, Theeuwes JW, Bacus SS. Qantitation of Her-2/neu oncoprotein overexpression in invazive breast cancer by image analysis:A study comparing fresh and paraffin-embedded material. Anal Cell Pathol 1991;3:195-202. 11-McCann AH, Dervan PA, O’Regan M et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-3303. 12-Thor AD, Schwartz LH, Koerner FC et al. Analysis of c- erbB-2expression in breast carcinomas with clinical follow-up. Cancer Res. 1989;49:7147-7152. 13-Yang Q, Sakurai T, Jing X, et al. Expression of bcl-2, but not bax, corralates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol Int 1999;49:775-780 14-Suzuki M, Okuyama T, Yoshikawa K, et al. Overexpression of p53, c-erbB-2 and epidermal growth factor receptor in human breast carcinomas. Pathology Int 1996;46:46-53. 15-Fukishima T, Urazumi K, Inoue N, et al. Significance of overexpression of p53 protein in human breast cancer:A clinicopathologic study. Jpn J Cancer Clin 1983;39:23-27. 16-Yang Q, Mori I, Sakurai T, e